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Abstract 
Hemorrhagic gastritis is a possible late toxicity outcome after radical radiotherapy but it is 
nowadays a very rare condition and most likely depends on other clinical factors. We report 
the case of a 77-year-old woman with a symptomatic solitary extramedullary intra-abdominal 
plasmacytoma and multiple gastric comorbidities, treated with external beam radiotherapy. 
Despite the good response to radiotherapy, the patient experienced multiple gastric bleed-
ing a few months later, with the need of multiple treatments for its control. In this paper we 
will discuss in detail all aspects related to the different causes of hemorrhagic gastritis. 
© 2015 S. Karger AG, Basel 
Introduction 
Primary extramedullary plasmacytoma (EMP) accounts for approximately 4% of all 
plasma cell neoplasms [1]. Solitary EMPs of the retroperitoneum are rare with few reports in 
the literature [2]. Plasma cell tumors tend to be radio- and chemosensitive; therefore, the 
treatment of choice for EMPs can either be surgery, chemotherapy or radiotherapy [3]. The 
best choice for treatment is not evident [2], but most cases are localized, and some studies 
have shown that radical radiotherapy offers potential local control and organ preservation 
associated with low toxicity [4–6]. However, post-radiotherapy gastritis is possible, and sev-
eral cases of bleeding have been reported [7, 8]. We present a case of gastritis after radio-
therapy treatment and analyze all possible causes in detail. 
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Case Presentation 
A 77-year-old female was referred to our Radiotherapy Department with newly diag-
nosed retroperitoneal solitary EMP. By the end of January 2012, the patient presented with 
abdominal pain and stomach fullness. An abdominal CT scan (February 2012) revealed a 
10.5 × 9.5 × 8 cm heterogeneous solid mass localized adjacent to the pancreas tail involving 
the aortic and renal arteries (fig. 1). A biopsy of the tumor (March 2012) was CD138+, lamb-
da light chain positive, had normal bone marrow and no skeletal lesions, which confirmed 
the diagnosis. Relevant personal history included a record of gastritis from Helicobacter py-
lori (HP) infection treated in 2008 and hyperplastic micropolyps, atrophic gastritis and ero-
sive gastritis in 2010, which was related to nonsteroidal anti-inflammatory drug intake. The 
patient was on dexamethasone (40 mg/day; 4 days/week every 2 weeks), darbopoetin (500 
μg bimonthly) and pantoprazole (40 mg/day). 
The patient was treated with conformal external radiotherapy and received a total dose 
of 48.6 Gy in 27 fractions (May 22 to June 29, 2012). The mean absorbed dose (stomach) was 
45.5 Gy with a maximum of 52.1 Gy. No organs at risk were compromised. Post-radiotherapy 
toxicity included gastrointestinal toxicity and leucopenia grade 2. Soon after treatment, the 
patient experienced relief of her symptoms. A 18F-FDG PET-CT scan performed 2 months 
later was unremarkable for abnormal metabolic uptake. 
By the end of October 2012, the patient suffered an episode of hematemesis. An endo-
scopic evaluation documented gastric angiectasis without active gastric bleeding. This epi-
sode was successfully treated with proton pump inhibitors. However, one month later, the 
patient was again admitted to the Emergency Room due to new and persistent gastric bleed-
ing unresponsive to endoscopic treatment (fig. 2) and required hemodynamic surveillance 
as well as intensive transfusion support. At that time, an endoscopy with gastric biopsies 
exhibited mild gastritis with focal activity and reparative mucosal changes. There was HP 
positivity in a low concentration (fig. 3), and malignancy was excluded. A CT scan was incon-
clusive. The patient was submitted to an exploratory laparotomy combined with intraopera-
tory endoscopy, and an active hemorrhagic ulcer localized on the lesser curvature was found 
and resolved. Despite surgical treatment, hemorrhagic emesis with clots persisted. Hyper-
baric oxygen treatment was then proposed. After 20 sessions of treatment, the patient no-
ticed a relief of symptoms and an imagiological response upon endoscopy was documented. 
Despite being asymptomatic for the next 5 months, in June 2013, the patient had another 
digestive bleeding episode. Endoscopy identified a small clot on the distal esophagus-
pigmented mucosa and gastric friable mucosa with neovasculature. Hyperbaric oxygen 
treatment was restarted, and a remarkable improvement in symptoms was noted. On the 
latest follow-up (October 2013), the patient was still on hyperbaric oxygen treatment and 
remained asymptomatic. A good tumor response to treatment was noted upon an abdominal 
CT scan, and an 18F-FDG PET-CT scan detected minor metabolic expression suggesting an 
inflammatory pattern (fig. 4). 
Discussion 
Radiotherapy is considered a plausible option for treating non-head-and-neck EMP as it 
achieves symptomatic control and is likely to be less toxic compared with surgery and 
chemotherapy [6]. Evidence of this fact is supported by individual cases in the literature 
although there are no clinical studies categorically confirming it [1–5]. In some cases, radio-
therapy is given after the failure of previous treatments, but in those cases, cumulative tox-
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icity may be expected. In the present case, the treatment was radiotherapy based, and re-
peated hemorrhagic episodes were linked to radiotherapy. In fact, our patient experienced 
two gastric bleeding episodes with the first occurring 4 months after radiotherapy, which 
may be interpreted as an expected late toxicity. However, this event is rare and was only 
reported in 5–7% of cases, which had higher doses. The absorbed dose in the whole stomach 
was 45 Gy based on updated recommendations [9]. The maximum point dose has been sug-
gested to be a good predictor for late toxicity [9]. Unfortunately, most studies evaluate doses 
between 40 and 50 Gy and do not take into account organ position variability [7, 9]. The 
initial injury from radiation is acute inflammation of the gastric mucosa. If the injury pro-
gresses, it may evolve to progressive vasculopathy, leading to mucosal ischemia, ulceration, 
and telangiectasia. The characteristic endoscopic finding is the presence of telangiectasia, 
which was observed during the first bleeding event. Bleeding is a diffuse process with multi-
ple bleeding sites [10]. Other findings may include diffuse erythema of the mucosa, shallow 
or deep ulcers, and scar formation. Although the morphological aspects observed in the most 
recent biopsies might be related to HP gastritis, reparative changes may also be related to 
radiation gastritis recovery. 
In contrast, HP presence after eradication may contribute to the reappearance of gastric 
ulcers and hemorrhaging and may be correlated with chronic gastritis activity independent 
from radiation injury [11, 12]. Unfortunately, few biopsies were performed during the last 
endoscopic examination [12, 13]. Only the examination of gastric vessels at some distance 
from the ulcers can be helpful in defining radiation as the cause because these will have ra-
diation-vasculopathy characteristics (neovascularization, telangiectasia, and obliterative 
intimal lesions) [13]. Moreover, in our patient, these vasculopathic features were not ob-
served, and only minor fibrosis was documented. 
Although the final histological diagnosis may be uncertain due to the lack of criteria, it is 
suggested that there may be an overlap of several causes. The patient’s previous stomach-
related disease, the presence of HP, and multiple endoscopic interventions (visible scars 
from multiples biopsies) are factors for potential gastric complications, which may be inde-
pendent from radiation effects or can alter the threshold for toxicity. Recognizing these fac-
tors in a particular patient increases the ability to predict potential radiotherapy-related 
toxicity as bleeding. To the best of our knowledge, no radiotherapy recommendations have 
addressed this question yet [7, 9]. 
In conclusion, radiotherapy is an option for the treatment of EMPs, offering an oppor-
tunity for the local control and relief of such a large tumor. 
Frequent complications such as hemorrhagic episodes secondary to HP gastritis may al-
so occur in patients with unusual diseases and comorbidities, highlighting the importance of 
clinical suspicion. 
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Fig. 1. CT scan performed in February 2012, revealed a retroperitoneal mass. 
 
 
D
ow
nl
oa
de
d 
by
: 
19
4.
38
.1
44
.1
9 
- 3
/1
2/
20
15
 1
2:
26
:2
1 
PM
13 
 
Case Rep Oncol 2015;8:9–14 
DOI: 10.1159/000371653 
 
© 2015 S. Karger AG, Basel 
www.karger.com/cro 
Abrunhosa-Branquinho et al.: A Case of Post-Radiotherapy Gastritis: Radiation Does 
Not Explain Everything 
 
 
 
 
Fig. 2. Low-debit hemorrhage on the upper portion of the lesser curvature documented by endoscopy on 
November 27, 2012 between the endoscopic treatments. 
 
 
 
Fig. 3. HP identification (red circle) on gastric biopsy on December 7, 2012. Modified Giemsa staining. 
×900. 
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Fig. 4. Documentation of radiotherapy response between by comparing the 18F-FDG PET-CT scans from 
October 2012 (left panel) and July 2013 (right panel). 
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